We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ARTES and Boehringer Ingelheim Animal Health Announce Collaboration
News

ARTES and Boehringer Ingelheim Animal Health Announce Collaboration

ARTES and Boehringer Ingelheim Animal Health Announce Collaboration
News

ARTES and Boehringer Ingelheim Animal Health Announce Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ARTES and Boehringer Ingelheim Animal Health Announce Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ARTES Biotechnology has announced a collaboration with the global pharmaceutical company Boehringer Ingelheim Animal Health.

ARTES’ expression system Hansenula polymorpha is the preferred technology for affordable mass vaccination and recommended by the World Health Organization (WHO) for these purposes. In combination with ARTES’ METAVAX® platform, this offers a new, unique and very economical approach to low-cost mass production of safe and effective vaccines required in the veterinary field.

“This collaboration is another milestone in expanding our vaccine development expertise”, Michael Piontek, managing director of ARTES stated. “We are more than confident that our technology platform is perfectly suited for the development of safe and cost efficient vaccines that are highly relevant for the veterinary market.”

“Partnering is a central part of our strategy. We are excited about this collaboration and the opportunity to develop more innovative vaccines for the animal health market,” says Rolf-Dieter Günther, Head of Global Business Development and Licensing Animal Health for Boehringer Ingelheim.

Advertisement